BioNTech SE
BNTXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · 2M · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2026-03-12Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
- Phase 3Active Not Recruitingreadout ~2026-07-23A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- Phase 3Active Not Recruitingreadout ~2026-07-31A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
- Phase 3Active Not Recruitingreadout ~2026-07-31A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
- Phase 1Active Not Recruitingreadout ~2026-10A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
- Phase 2Active Not Recruitingreadout ~2026-11A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- Phase 2Recruitingreadout ~2027-06A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
- Phase 1Active Not Recruitingreadout ~2027-06Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Sahin UgurPassive (13G)May 15, 2026
- Athos KgPassive (13G)May 14, 2026
- Medine GmbhPassive (13G)May 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.5M | 2.6 | +10.7% |
| Apr 30, 2026 | 2.2M | 2.5 | -31.2% |
| Apr 15, 2026 | 3.2M | 4.2 | -8.3% |
| Mar 31, 2026 | 3.5M | 3.4 | -0.8% |
| Mar 13, 2026 | 3.5M | 1.4 | -20.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.